Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Dare Bioscience (DARE) over the last 11 years, with Q3 2025 value amounting to $5.7 million.

  • Dare Bioscience's Non-Current Assets rose 8455.71% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.6 million, marking a year-over-year increase of 7831.33%. This contributed to the annual value of $3.7 million for FY2024, which is 228.44% down from last year.
  • As of Q3 2025, Dare Bioscience's Non-Current Assets stood at $5.7 million, which was up 8455.71% from $6.4 million recorded in Q2 2025.
  • Dare Bioscience's 5-year Non-Current Assets high stood at $6.8 million for Q1 2025, and its period low was $511161.0 during Q4 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $1.4 million (2022), whereas its average is $2.5 million.
  • Data for Dare Bioscience's Non-Current Assets shows a peak YoY increase of 37467.41% (in 2023) and a maximum YoY decrease of 3758.36% (in 2023) over the last 5 years.
  • Dare Bioscience's Non-Current Assets (Quarter) stood at $511161.0 in 2021, then surged by 54.09% to $787630.0 in 2022, then soared by 374.67% to $3.7 million in 2023, then dropped by 2.28% to $3.7 million in 2024, then skyrocketed by 57.24% to $5.7 million in 2025.
  • Its Non-Current Assets stands at $5.7 million for Q3 2025, versus $6.4 million for Q2 2025 and $6.8 million for Q1 2025.